Assessment of therapeutic response in patients with metastatic bone disease.

2.50
Hdl Handle:
http://hdl.handle.net/10541/78441
Title:
Assessment of therapeutic response in patients with metastatic bone disease.
Authors:
Clamp, Andrew R; Danson, Sarah; Nguyen, Huy; Cole, David; Clemons, Mark
Abstract:
Metastatic bone disease is common in cancer patients and causes substantial disease-related morbidity and mortality. However, several effective treatments are available for the management of these patients. Bisphosphonates, which inhibit osteoclast-mediated resorption of bone matrix, are especially important because they decrease the incidence of skeletal-related events in many tumour types and can complement antineoplastic therapies. At present, assessment of treatment for bone metastases is hindered by a lack of effective, rapid methods to measure disease response. We discuss the difficulties of current measures of response assessment and describe the development of new radiological and biochemical markers of bone metastases. Assays that detect type I collagen telopeptides as markers of bone resorption seem to be most promising at present.
Affiliation:
Cancer Research UK, Department of Medical Oncology, Christie Hospital, Manchester, UK.
Citation:
Assessment of therapeutic response in patients with metastatic bone disease. 2004, 5 (10):607-16 Lancet Oncol.
Journal:
The Lancet Oncology
Issue Date:
Oct-2004
URI:
http://hdl.handle.net/10541/78441
DOI:
10.1016/S1470-2045(04)01596-7
PubMed ID:
15465464
Type:
Article
Language:
en
ISSN:
1470-2045
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorClamp, Andrew R-
dc.contributor.authorDanson, Sarah-
dc.contributor.authorNguyen, Huy-
dc.contributor.authorCole, David-
dc.contributor.authorClemons, Mark-
dc.date.accessioned2009-08-25T11:02:59Z-
dc.date.available2009-08-25T11:02:59Z-
dc.date.issued2004-10-
dc.identifier.citationAssessment of therapeutic response in patients with metastatic bone disease. 2004, 5 (10):607-16 Lancet Oncol.en
dc.identifier.issn1470-2045-
dc.identifier.pmid15465464-
dc.identifier.doi10.1016/S1470-2045(04)01596-7-
dc.identifier.urihttp://hdl.handle.net/10541/78441-
dc.description.abstractMetastatic bone disease is common in cancer patients and causes substantial disease-related morbidity and mortality. However, several effective treatments are available for the management of these patients. Bisphosphonates, which inhibit osteoclast-mediated resorption of bone matrix, are especially important because they decrease the incidence of skeletal-related events in many tumour types and can complement antineoplastic therapies. At present, assessment of treatment for bone metastases is hindered by a lack of effective, rapid methods to measure disease response. We discuss the difficulties of current measures of response assessment and describe the development of new radiological and biochemical markers of bone metastases. Assays that detect type I collagen telopeptides as markers of bone resorption seem to be most promising at present.en
dc.language.isoenen
dc.subjectBone Canceren
dc.subjectBiological Tumour Markersen
dc.subject.meshAbsorptiometry, Photon-
dc.subject.meshBone Neoplasms-
dc.subject.meshBone Remodeling-
dc.subject.meshHumans-
dc.subject.meshMagnetic Resonance Imaging-
dc.subject.meshTomography, Emission-Computed-
dc.subject.meshTomography, X-Ray Computed-
dc.subject.meshTreatment Outcome-
dc.subject.meshTumor Markers, Biological-
dc.titleAssessment of therapeutic response in patients with metastatic bone disease.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK, Department of Medical Oncology, Christie Hospital, Manchester, UK.en
dc.identifier.journalThe Lancet Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.